Product Review Keytruda for NSCLC

This review is a concise summary of the important pharmacological and clinical characteristics of
pembrolizumab (Keytruda®), which is available, but not currently funded, in New Zealand for the treatment
of non-small cell lung cancer (NSCLC). Expert commentary on the use of pembrolizumab from a clinical
practice perspective is provided by Dr Tony Rahman.

Please login below to download this issue (PDF)